A Randomized, Open-label, Single-dose, Two-sequence, and Two-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of AD-115A and the Administration of AD-1151 for Healthy Subjects in Fasting State
Latest Information Update: 13 Feb 2026
At a glance
- Drugs AD 115A (Primary)
- Indications Gastric ulcer
- Focus Pharmacokinetics
Most Recent Events
- 10 Feb 2026 New trial record